Experience real-time quotes, in-depth charts, and analyst ratings

MARKET

DRIO

Dariohealth Corp

NASDAQ

5.14

+0.41

+8.67%

After Hours: 5.19 +0.05 +0.97% 16:02 10/04 EDT

OPEN

4.820

PREV CLOSE

4.730

HIGH

5.36

LOW

4.820

VOLUME

228.07K

TURNOVER

52 WEEK HIGH

19.39

52 WEEK LOW

3.660

MARKET CAP

118.11M

P/E (TTM)

-1.1975

DarioHealth Publishes New Clinical Research Linking The Use Of Its Biofeedback Device To Reduced Back Pain At The International Association Of The Study Of Pain 2022 World Congress On Pain, Toronto, Ontario From September 19–23

New research sheds light on the importance of training to drive healthier posture NEW YORK, Sept. 22, 2022 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO), a leader in the global digital therapeutics

Benzinga · 09/22 12:24

US Stocks Open Higher Ahead Of Fed Decision, Dow Jumps 175 Points

U.S. stocks traded higher this morning, with the Dow Jones gaining around 175 points on Wednesday. The Federal Reserve will announce its policy decision at 2:00 p.m. ET. The country’s central bank is widely expected to raise interest rates by 75 bps at the meeting. Fed Chairman Jerome Powell will hold a press conference at 2:30 p.m. ET.

Benzinga · 09/21 14:15

BRIEF-DarioHealth Announces New Employer Contracts

Reuters · 09/20 13:23

DarioHealth Announces Two New Employer Contracts

NEW YORK, Sept. 20, 2022 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company" or "Dario"), a leader in the global digital therapeutics (DTx) market, announced today two new

Benzinga · 09/20 12:06

Looking Into DarioHealth's Return On Capital Employed

Benzinga Pro data, DarioHealth (NASDAQ:DRIO) reported Q2 sales of $6.18 million. Earnings fell to a loss of $18.03 million, resulting in a 13.27% decrease from last quarter.

Benzinga · 09/09 14:18

Aegis Capital Maintains Buy on DarioHealth, Lowers Price Target to $15

Aegis Capital analyst Nathan Weinstein maintains DarioHealth (NASDAQ:DRIO) with a Buy and lowers the price target from $20 to $15.

Benzinga · 08/18 13:33

Cowen & Co. Maintains Outperform on DarioHealth, Lowers Price Target to $14

Cowen & Co. analyst Charles Rhyee maintains DarioHealth (NASDAQ: DRIO) with a Outperform and lowers the price target from $18 to $14.Cowen & Co.

Benzinga · 08/18 05:37

DRIO: Suite Solution

By John Vandermosten, CFA NASDAQ:DRIO READ THE FULL DRIO RESEARCH REPORT Second Quarter 2022 Financial and Operational Results On August 15, 2022, DarioHealth Corp. (NASDAQ:DRIO) published its second quarter 2022 operational and financial results in a pres...

Zacks Small Cap Research · 08/16 15:45

About DRIO

DarioHealth Corp. (DarioHealth) is a Digital Therapeutics (DTx) company. DarioHealth operates at the intersection of life sciences, behavioral science, and software technology to deliver integrated and engaging digital therapeutics interventions. DarioHealth offers digital therapeutics solutions covering multiple chronic conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health within one integrated technology platform. Its products include Dario Blood Glucose Monitoring Starter Kit and Dario Blood Pressure Monitoring System. Its Dario Blood Glucose Monitoring Starter Kit is pocket-sized smartphone blood glucose meter that measure sugar levels. Its Dario Blood Pressure Monitoring System is a blood pressure monitoring system used to measure blood pressure, which allows to store all your readings in the Dario App. Its Dario mobile application, the Dario Blood sugar (glucose) meter enables to track and check blood sugar (glucose) in real-time.

Webull offers kinds of DarioHealth Corp stock information, including NASDAQ:DRIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DRIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DRIO stock methods without spending real money on the virtual paper trading platform.